Guggenheim Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $70

Benzinga · 2d ago
Guggenheim analyst Yatin Suneja initiates coverage on Korsana Biosciences (NASDAQ:KRSA) with a Buy rating and announces Price Target of $70.